References
- Ali A, Black D, Soslow RA (2007). Difficulties in assessing the depth of myometrial invasion in endometrial carcinoma. Int J Gynecol Pathol, 26, 115-23. https://doi.org/10.1097/01.pgp.0000233165.56385.0b
- Angioli R, Plotti F, Capriglione S, et al (2013). The role of novel biomarker HE4 in endometrial cancer: a case control prospective study. Tumour Biol, 34, 571-6. https://doi.org/10.1007/s13277-012-0583-0
- Antonsen SL, Hogdall E, Christensen IJ, et al (2013). HE4 and CA125 levels in the preoperative assessment of endometrial cancer patients: a prospective multicenter study (ENDOMET). Acta Obstet Gynecol Scand, 92, 1313-22. https://doi.org/10.1111/aogs.12235
- Bignotti E, Ragnoli M, Zanotti L, et al (2011). Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients. Br J Cancer, 104, 1418-25. https://doi.org/10.1038/bjc.2011.109
- Bolstad N, Oijordsbakken M, Nustad K, et al (2012). Human epididymis protein 4 reference limits and natural variation in a Nordic reference population. Tumour Biol, 33, 141-8. https://doi.org/10.1007/s13277-011-0256-4
- Brennan DJ, Hackethal A, Metcalf AM, et al (2014). Serum HE4 as a prognostic marker in endometrial cancer--a population based study. Gynecol Oncol, 132, 159-65. https://doi.org/10.1016/j.ygyno.2013.10.036
- Cancer in Thailand (2010). Bangkok, Ministry of public health.
- Creasman WT, Odicino F, Maisonneuve P, et al (2006). Carcinoma of the corpus uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet, 95, 105-43. https://doi.org/10.1016/S0020-7292(06)60031-3
- Drapkin R, von Horsten HH, Lin Y, et al (2005). Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res, 65, 2162-9. https://doi.org/10.1158/0008-5472.CAN-04-3924
- Jemal A, Siegel R, Ward E, et al (2008). Cancer statistics. CA Cancer J Clin, 58, 71-96. https://doi.org/10.3322/CA.2007.0010
- Jhang H, Chuang L, Visintainer P, et al (2003). CA 125 levels in the preoperative assessment of advanced-stage uterine cancer. Am J Obstet Gynecol, 188, 1195-7. https://doi.org/10.1067/mob.2003.304
- Kalogera E, Scholler N, Powless C, et al (2012). Correlation of serum HE4 with tumor size and myometrial invasion in endometrial cancer. Gynecol Oncol, 124, 270-5. https://doi.org/10.1016/j.ygyno.2011.10.025
- Mariani A, Dowdy SC, Cliby WA, et al (2008). Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging. Gynecol Oncol, 109, 11-8. https://doi.org/10.1016/j.ygyno.2008.01.023
- Mariani A, Webb MJ, Keeney GL, et al (2000). Low-risk corpus cancer: is lymphadenectomy or radiotherapy necessary?. Am J Obstet Gynecol, 182, 1506-19. https://doi.org/10.1067/mob.2000.107335
- Moore RG, Brown AK, Miller MC, et al (2008). Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. Gynecol Oncol, 110, 196-201. https://doi.org/10.1016/j.ygyno.2008.04.002
- Moore RG, Miller CM, Brown AK, et al (2011). Utility of tumor marker HE4 to predict depth of myometrial invasion in endometrioid adenocarcinoma of the uterus. Int J Gynecol Cancer, 21, 1185-90.
- Movahedi-Lankarani S, Gilks C, Soslow R, et al (2009). Protocol for the examination of specimens from patients with carcinoma of the endometrium. college of american pathologists (CAP).
- Mutz-Dehbalaie I, Egle D, Fessler S, et al (2012). HE4 is an independent prognostic marker in endometrial cancer patients. Gynecol Oncol, 126, 186-91. https://doi.org/10.1016/j.ygyno.2012.04.022
- Powell JL, Hill KA, Shiro BC, et al (2005). Preoperative serum CA-125 levels in treating endometrial cancer. J Reprod Med, 50, 585-90.
- Takeshima N, Shimizu Y, Umezawa S, et al (1994). Combined assay of serum levels of CA125 and CA19-9 in endometrial carcinoma. Gynecol Oncol, 54, 321-6. https://doi.org/10.1006/gyno.1994.1217
- Trovik J, Mauland KK, Werner HM, Wik E, et al (2012). Improved survival related to changes in endometrial cancer treatment, a 30-year population based perspective. Gynecol Oncol, 125, 381-7. https://doi.org/10.1016/j.ygyno.2012.01.050
- Vargas R, Rauh-Hain JA, Clemmer J, et al (2014). Tumor size, depth of invasion, and histologic grade as prognostic factors of lymph node involvement in endometrial cancer: a SEER analysis. Gynecol Oncol, 133, 216-20. https://doi.org/10.1016/j.ygyno.2014.02.011
- Youden WJ (1950). Index for rating diagnostic tests. Cancer, 3, 32-5. https://doi.org/10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3
Cited by
- Discovery of biomarkers for endometrial cancer: current status and prospects vol.16, pp.12, 2016, https://doi.org/10.1080/14737159.2016.1258302
- HE4-test of urine and body fluids for diagnosis of gynecologic cancer vol.17, pp.3, 2017, https://doi.org/10.1080/14737159.2017.1282824
- Human Epididymis Protein 4 Promotes Events Associated with Metastatic Ovarian Cancer via Regulation of the Extracelluar Matrix vol.7, pp.2234-943X, 2018, https://doi.org/10.3389/fonc.2017.00332
- Beyond the Biomarker: Understanding the Diverse Roles of Human Epididymis Protein 4 in the Pathogenesis of Epithelial Ovarian Cancer vol.8, pp.2234-943X, 2018, https://doi.org/10.3389/fonc.2018.00124